Plasma estrogen monitoring of ovulation induction.
Eight hMG-hCG therapy cycles in 6 anovulatory infertile patients are presented. Daily plasma estrogen monitoring during the therapy contributed to success in inducing ovulation in all 6, 3 of whom established pregnancies and delivered healthy babies. The duration of hMG therapy required varies among individuals. Duration and dosage can be determined on the basis of daily plasma estrogen levels. Administration hCG is recommended to trigger ovulation when these levels reach 300 to 600 pg/ml. Although success in ovulation induction and pregnancy is achievable, multiple ovulation and multiple pregnancy cannot be predicted or prevented.
D000328:Adult; D000568:Amenorrhea / Q000150:complications; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D004967:Estrogens / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000150:complications; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000494:pharmacology / Q000627:therapeutic use; D010060:Ovulation / Q000187:drug effects; D010061:Ovulation Detection / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011374:Progesterone / Q000097:blood
D006063:Chorionic Gonadotropin; D004967:Estrogens; D002996:Clomiphene; D011374:Progesterone; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone